• Artrya secures commercial contract with Lumus Imaging for use of Salix® Coronary Anatomy platform
• Lumus Imaging to first deploy Salix® at its St George centre in New South Wales
• Agreement represents a world-class collaboration as Lumus Imaging is one of only two imaging centres in the southern hemisphere equipped with the world-leading Photon Counting CT scanner

Artrya Limited (ASX:AYA), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, has secured a commercial contract with Lumus Imaging (Lumus) for the use of Salix® Coronary Anatomy platform. Lumus, one of Australia's leading diagnostic imaging providers, operates 150 Imaging centres nationally. Under a 36-month agreement, the Salix® Coronary Anatomy platform will first be integrated into Lumus Imaging's centre at St George Private Hospital, Sydney. Lumus will leverage Salix® to accurately and efficiently detect critical markers, including high-risk plaque, from CT coronary angiogram (CTCA) scans generated by a Photon Counting CT scanner. Notably, Lumus Imaging is one of only two centres in the southern hemisphere equipped with this cutting-edge scanner, regarded as the most advanced CT technology globally. The agreement between Lumus Imaging and Artrya represents a significant step forward in leveraging advanced technology for improved patient care. Artrya's unique AI solution, combined with the world-leading Photon Counting CT Scanner, introduces a groundbreaking innovation with a revolutionary scanner that delivers significantly higher-definition images than traditional CT machines, while reducing exposure to harmful radiation. By integrating Artrya's AI capabilities with the Photon Counting CT Scanner at the St George centre, Lumus Imaging reinforces its commitment to cutting-edge innovation and providing world-class patient care.

The 36-month contract will generate revenue through a Software-as-a-Service (SaaS) subscription model.